Ruplizumab( —— )

Catalog No. M36733 CAS No. 220651-94-5

Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	369	Get Quote
5MG	601	Get Quote
10MG	823	Get Quote
25MG	1178	Get Quote
50MG	1592	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Ruplizumab
Note

Research use only, not for human use.
Brief Description

Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
Description

Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

220651-94-5
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Chris Chamberlain, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017 Nov;76(11):1837-1844.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks